- Global Pharma News & Resources

Zur Rose Group broadens its leadership structure and completes Group Management

EQS Group-News: Zur Rose Group AG / Key word(s): Personnel
12.03.2020 / 06:45

Press release

Zur Rose Group broadens its leadership structure and completes Group Management

- Expansion of leadership structure in line with corporate strategy

- Focus on markets and business models reinforcing proximity to customers

- Group Management completed with appointment of David Masó as Head Europe

Zur Rose is adapting its leadership structure to the needs and opportunities of the Group that has seen strong growth. The Board of Directors has decided to further refine the organisation of the company with the aim of reinforcing proximity to customers and making the organisation more agile. In addition to the existing segment organisation with both regional and revenue responsibility, a cross-segment business model organisation with the following responsibilities is being put in place: Walter Hess will run the B2B2C & B2B business model in addition to the Switzerland segment, Olaf Heinrich will run the B2C business model in addition to the Germany segment and David Masó will be taking on responsibility for Europe (outside Germany, Austria and Switzerland) and the marketplace model. This will allow the Zur Rose Group to use business model-specific expertise across countries and profit from synergies.

The market segments and business models will be supported by two new service units: Strategy and Digitalisation as well as Operations. As previously announced, these will be headed by Betül Susamis Unaran as Chief Strategy and Digital Officer and Bernd Gschaider as Chief Operations Officer with effect from 1 May 2020. The new Group Management will thereafter consist of seven seasoned managers. Walter Oberhänsli emphasised: "With the new, broader leadership structure we are accelerating digitalisation initiatives and focusing rigorously on customers. Responsibility will be spread across several pairs of shoulders, making Zur Rose more agile and effective."

Strengthening of Group Management: David Masó to become Head Europe
As part of the new organisation, the Zur Rose Group has appointed David Masó as Head of the Europe segment with effect from 1 May 2020. David Masó has been CEO of the e-commerce marketplace PromoFarma in Barcelona since 2012, which he will retain in addition to performing his Group management function. He will also be responsible for the marketplace business model on a Group level. David Masó founded PromoFarma, which has developed into southern Europe's leading marketplace for consumer health, beauty and personal care products commonly sold in pharmacies, together with Adrià Carulla eight years ago. The two founders sold the company to the Zur Rose Group in 2018. Before his involvement with PromoFarma David Masó co-founded several successful e-commerce start-ups. The Spanish citizen is 48 years old, a telecoms engineer and holds an MBA. Walter Oberhänsli is delighted at the appointment: "David Masó is an entrepreneur with an impressive track record. I am confident that his excellent skills in technology and e-commerce make him the ideal person for this position, given the intended further geographical expansion of the Zur Rose Group."

Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email:, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Group Communications
Email:, phone: +41 52 724 08 14

19 March 2020 2019 Full-Year Results
16 April 2020 First Quarter Trading Update
23 April 2020 Annual General Meeting
19 August 2020 Half-Year Results
21 October 2020 Q3 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,570 million (including medpex) and has around seven million active customers in core European markets.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see

End of Corporate News

Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Phone: +41 52 724 08 14
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 993737

End of News EQS Group News Service

Editor Details

Last Updated: 12-Mar-2020